CRISPR And Cas Genes Market Size to Surpass USD 9.85 Bn by 2030
According to the global CRISPR And Cas Genes market size is expected to surpass around USD 9.85 billion by 2030 from valued at USD 2.09 billion in 2021 and growing at a CAGR of 17.60% from 2022 to 2030.
Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7107
- By product and services, the product segment dominated the industry in 2021 due to the availability of a broad range of product portfolios & rising adoption by various end-users
- The biomedical segment dominated the industry in 2021. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth
- The biotechnology & pharmaceutical companies’ end-use segment captured the major revenue share in 2021. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification
- North America captured the highest revenue share in 2021 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics
owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.
The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher’s emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.
Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.
It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company’s CRISPR genes-driven diagnostics portfolio.
Report Scope of the CRISPR And Cas Genes Market
USD 9.85 Billion by 2030
CAGR of 17.60% from 2022 to 2030
Fastest Growing Market
2022 to 2030
Product & service, application, end-use and Region,
AstraZeneca; Addgene; Caribou Biosciences, Inc.; Cellectis; CRISPR Therapeutics; Editas Medicine, Inc.; eGenesis; F. Hoffmann-La Roche Ltd.; Horizon Discovery Group plc; GenScript; Danaher Corp.; Intellia Therapeutics, Inc.; Lonza; Merck KGaA; Intellia Therapeutics, Inc.; Takara Bio Inc.; Thermo Fisher Scientific, Inc.; Synthego; Mammoth Biosciences; Inscripta, Inc.; Cibus; Beam Therapeutics; PLANTeDIT; Vertex Pharmaceuticals Incorporated; Hera BioLabs; OriGene Technologies, Inc.; Recombinetics, Inc.
Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7107
Product & Service Insights
Based on product & service, the global industry has been further categorized into products and services. The product segment dominated the global industry in 2021 and accounted for the highest share of more than 79.10% of the overall revenue. Several cutting-edge technologies, such as CRISPR gene editing kits, have been developed to meet the growing demands for genome editing solutions. The maximum revenue share can be attributed to the availability of enhanced individual products that can be used to achieve a variety of goals, including simple gene knockouts, selective genome cleavage, reduced off-target cutting, genome engineering, and higher specificity.
Furthermore, increased investments in gene editing-based R&D, along with the introduction of several applications, are anticipated to drive the growth of the service segment during the forecast period. For instance, in July 2022, a U.K. charity (The British Heart Foundation) provided USD 36 million to an international team to develop innovative gene-editing treatments for inherited heart diseases. Recent gene editing techniques, particularly CRISPR technology, have offered several opportunities to combat cardiovascular diseases.
On the basis of applications, the global industry has been further categorized into biomedical and agricultural. The biomedical application segment dominated the global industry in 2021 and accounted for the largest share of more than 92.85% of the total revenue. The increasing utilization of CRISPR gene-editing technologies in a number of biological science fields has significantly contributed to the segment’s high revenue share. The effectiveness and specificity of this technology have been enhanced by better delivery methods and the introduction of nanocarriers. The number of studies and publications that use this method to modify the genomes of human somatic cells and induced pluripotent stem cells has significantly increased.
In addition, some companies provide commercial kits and services to help researchers who are working in this domain. On the other hand, the agriculture application segment is anticipated to register the fastest growth rate during the forecast period. Improvements in agricultural production through the incorporation of innovative breeding technology have increased access to nutrition-rich foods globally. For instance, in June 2019, researchers at the Cold Spring Harbor Laboratory implemented CRISPR/Cas9 technology to induce mutations in the flowering suppressor of tomatoes, which resulted in rapid flowering and improved compact growth of tomatoes, finally an early yield.
On the basis of end-uses, the global industry has been further categorized into biotechnology & pharmaceutical companies, academics & government research institutes, and Contract Research Organizations (CROs). The biotechnology and pharmaceutical companies end-use segment dominated the global industry in 2021 and accounted for the maximum share of more than 49.20% of the overall revenue. Pharmaceutical companies are utilizing these technologies more frequently to quickly identify and validate new therapeutic targets and to produce better biological models for human diseases in less time.
The segment is also anticipated to be further driven by the rising number of biotechnology companies using gene modification for both research and commercial purposes. In addition, there is a huge demand for CRISPR-based gene-editing methods for the creation of innovative medicines for cell and gene therapies. CRISPR’s core architecture has been modified by extending its reach into the epigenome and granting control over an epigenetic inheritance. For instance, in April 2021, researchers from the Massachusetts Institute of Technology and the University of California created a CRISPR on-off switch to regulate gene expression.
On the basis of geographies, the global industry has been further categorized into North America, Europe, Latin America, Middle East & Africa, and Asia Pacific. The North American region dominated the global industry in 2021 and accounted for the maximum share of more than 38.40% of the overall revenue. The growing biopharmaceutical R&D as well as the involvement of several pharmaceutical corporations in the creation of novel therapeutics has contributed to the region’s growth. For instance, in May 2020, Merck KGaA received U.S. approval for two of its CRISPR Cas9-driven gene-editing patents.
Asia Pacific, on the other hand, is anticipated to witness the fastest growth rate during the forecast period. The increasing government investment in R&D to develop novel treatments is aiding in the market expansion in Japan and China. For instance, in March 2021, Japanese biotech company Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics. The company is creating animal and cell models using these advanced technologies. Such initiatives are predicted to enhance CRISPR technology adoption in the region, further contributing to revenue generation.
Some of the prominent players in the CRISPR And Cas Genes Market include:
- AstraZeneca plc
- Caribou Biosciences, Inc.
- Cellectis, CRISPR Therapeutics
- Editas Medicine, Inc.
- F. Hoffmann-La Roche Ltd.
- Horizon Discovery Group plc
- Danaher Corp.
- Intellia Therapeutics, Inc.
- Merck KGaA
- Intellia Therapeutics, Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific, Inc.
- Mammoth Biosciences
- Inscripta, Inc.
- Beam Therapeutics
- Vertex Pharmaceuticals Inc.
- Hera BioLabs
- OriGene Technologies, Inc.
- Recombinetics, Inc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global CRISPR And Cas Genes market
- Product & Service
- By Product
- Kits & Enzymes
- Vector-based Cas
- DNA-free Cas
- Design Tool
- Kits & Enzymes
- By Service
- Cell Line Engineering
- gRNA Design
- Microbial Gene Editing
- DNA Synthesis
- By Product
- Genome Engineering
- Disease Model Studies
- Functional Genomics
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- Contract Research Organizations (CROs)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7107
You can place an order or ask any questions, please feel free to email@example.com| +1 9197 992 333